ClinicalTrials.Veeva

Menu

Mesenchymal Stem Cell-derived Pleiotropic Factor in the Treatment of Donor Sites

C

Chinese PLA General Hospital (301 Hospital)

Status and phase

Unknown
Phase 1

Conditions

Evaluate the Safety and Effectiveness of Mesenchymal Stem Cell Conditioned Medium-derived Pleiotropic Factor in Treating Donor Sites

Treatments

Biological: mesenchymal stem cell conditioned medium-derived pleiotropic factor

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Skin grafting is a standard treatment for deep wounds, but care of the donor site after transplantation is very important. The means of accelerating wound healing can increase overall patient satisfaction. In recent years, cytokine therapy has been an important strategy to promote tissue repair.Mesenchymal stem cells (MSC) have been considered the star cells that promote tissue repair. It works mainly through paracrine. Many biological effectors, including IGF-1, vascular endothelial growth factor (VEGF), TGF-β1, and hepatocyte growth factor (HGF), have been found and reported in various MSC conditioned media (MSC-CM), And play a role in promoting tissue repair and regeneration. In here, we aim to explore the MSC-CM-derived pleiotropic factor in treating donor sites and further evaluate its safety and effectiveness

Enrollment

20 estimated patients

Sex

All

Ages

6 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Mainly mild to moderate burns, III ° burn area is less than 20% (trauma factor is thermal burn); Thick-thickness skin (thickness 0.2-0.3mm), donor area and medium-thickness skin (thick 0.3-0.5mm) for the skin area study separately; Psychologically stable and able to complete the test process-

Exclusion criteria

History of clotting disorders, uncontrolled diabetes; Drug abuse, excessive drinking, malignant or autoimmune diseases, chemotherapy and immunosuppressive therapy; Significant local infection or combined systemic infection; Patients with severe heart, lung, liver, kidney, blood system and mental and nervous system diseases; Women during pregnancy and lactation-

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

20 participants in 2 patient groups

control group
No Intervention group
Description:
no intervention
experimental group
Experimental group
Description:
mesenchymal stem cell conditioned medium-derived pleiotropic factor
Treatment:
Biological: mesenchymal stem cell conditioned medium-derived pleiotropic factor

Trial contacts and locations

1

Loading...

Central trial contact

Meirong Li, doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems